XML 22 R12.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Fair Value Measurements | 3 Months Ended
--- | ---
Dec. 30, 2023
Fair Value Disclosures [Abstract] |
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] | Fair Value Measurements Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis The Company has investments in derivative instruments comprised of interest rate swaps and forward foreign currency contracts, which are valued using analyses obtained from independent third-party valuation specialists based on market observable inputs, representing Level 2 assets. The fair values of these derivative contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer to Note 11 for further discussion and information on derivative contracts. In addition, the Company has contingent consideration liabilities that are recorded at fair value, which is based on Level 3 inputs. The contingent consideration liability as of December 30, 2023 and December 31, 2022 was primarily related to the Acessa acquisition. Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at December 30, 2023:
|  |  | Fair Value at Reporting Date Using
| Balance as of December 30, 2023 |  | Quoted Prices in Active Market for Identical Assets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3)
Assets: |  |  |  |  |  |  |
Interest rate swaps | $ | 8.2 |  |  | $ | — |  |  | $ | 8.2 |  |  | $ | — |
Total | $ | 8.2 |  |  | $ | — |  |  | $ | 8.2 |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |
Contingent consideration | $ | 3.7 |  |  | $ | — |  |  | $ | — |  |  | $ | 3.7 |
Forward foreign currency contracts | 4.1 |  |  | — |  |  | 4.1 |  |  | — |
Total | $ | 7.8 |  |  | $ | — |  |  | $ | 4.1 |  |  | $ | 3.7 |
Liabilities Measured and Recorded at Fair Value on a Recurring Basis Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of contingent consideration liabilities, during the three month periods ended December 30, 2023 and December 31, 2022 were as follows:
|  | Three Month Ended |  |
|  | December 30, 2023 |  | December 31, 2022 |  |  |  |
Balance at beginning of period | $ | 2.0 |  |  | $ | 23.4 |  |  |  |  |
| Contingent consideration recorded at acquisition | — |  |  | — |  |  |  |  |
| Fair value adjustments | 1.7 |  |  | — |  |  |  |  |
| Payments | — |  |  | — |  |  |  |  |
Balance at end of period | $ | 3.7 |  |  | $ | 23.4 |  |  |  |  |
Assets Measured and Recorded at Fair Value on a Nonrecurring Basis The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets are comprised of equity investments and long-lived assets, including property, plant and equipment, intangible assets, and goodwill. During the first quarter of fiscal 2024, the Company recorded a $12.5 million impairment charge for right of use lease assets related to the expected closure of facilities in the Diagnostics division (see Note 8 for further discussion). In addition, during the first quarter of fiscal 2024, the Company recorded a $4.3 million impairment charge for an in-process research and development project from the Mobidiag acquisition, reducing the fair value of this asset to $22.4 million. There were no other remeasurements in the three months ended December 30, 2023 and December 31, 2022. Disclosure of Fair Value of Financial Instruments The Company’s financial instruments mainly consist of cash and cash equivalents, accounts receivable, equity investments, interest rate swaps, forward foreign currency contracts, insurance contracts, accounts payable and debt obligations. The carrying amounts of the Company’s cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company’s interest rate swaps and forward foreign currency contracts are recorded at fair value. The carrying amount of the insurance contracts are recorded at the cash surrender value, as required by U.S. GAAP, which approximates fair value. The Company believes the carrying amounts of its equity investments approximate fair value. Amounts outstanding under the Company’s 2021 Credit Agreement of $1.2 billion aggregate principal as of December 30, 2023 are subject to variable rates of interest based on current market rates, and as such, the Company believes the carrying amount of these obligations approximates fair value. The Company’s 4.625% Senior Notes due 2028 (the “2028 Senior Notes”) and 3.250% Senior Notes due 2029 (the “2029 Senior Notes”) had fair values of $386.3 million and $858.0 million, respectively, as of December 30, 2023 based on their trading prices, representing a Level 1 measurement. Refer to Note 9 for the carrying amounts of the various components of the Company’s debt.

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//820/tableOfContent + Details
Name: | us-gaap_FairValueMeasurementInputsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration